Step 1 — Volume Calculation

Calculate the total volume of COSENTYX for intravenous use solution (in mL) required based on the patient’s actual body weight:

*Maximum maintenance dose is 300 mg per infusion.

• Use the number of vials based on total volume needed (one vial contains 5 mL of COSENTYX solution)

Step 2 — Dilution

• Visually inspect the vial(s). The solution must be clear to opalescent, colorless to slightly yellowish. Do not use if particles or discoloration are observed 

• Use a 100-mL infusion bag for loading and maintenance doses, except for maintenance doses for patients ≤60 kg for whom a 50-mL infusion bag should be used. If a 50-mL infusion bag is unavailable, then use a 100-mL infusion bag and withdraw and discard 50 mL of saline using aseptic technique and continue to follow the preparation and administration steps 

• Withdraw and discard a volume of 0.9% Sodium Chloride Injection, USP from the infusion bag equal to the calculated volume of COSENTYX 

• Withdraw the calculated volume of COSENTYX from the vial(s) and add slowly into the 0.9% Sodium Chloride infusion bag. Gently invert the bag to mix. Do not shake. Discard unused product in vials 

• Allow the diluted solution to warm to room temperature before infusion 

• Administer as soon as possible. If not used immediately, store either at room temperature (20°C to 25°C/68°F to 77°F) for up to 4.5 hours or refrigerate (2°C to 8°C/36°F to 46°F) for up to 24 hours from the start of preparation to the completion of infusion (including warming time; protect from light)

Step 3 — Administration

• Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer) 

• Administer the infusion at a flow rate of about 3.3 mL/minute for a 100-mL bag or 1.7 mL/minute for a 50-mL bag (total administration time: 30 minutes) 

• When administration is complete, flush the line with 0.9% Sodium Chloride Injection, USP to guarantee that all the COSENTYX solution for infusion in the line has been administered 

• Do not infuse COSENTYX concomitantly in the same intravenous line with other drugs. No physical or biochemical compatibility studies have been conducted to evaluate the IV coadministration of COSENTYX with other drugs

Definitions 

HS, hidradenitis suppurativa; IL, interleukin; IV, intravenous; Q2W, every 2 weeks; SC, subcutaneous. 

References 

1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
2. Data on file. Cosentyx HS biologic prescriptions. Novartis Pharmaceuticals Corp; August 2026. 
3. Bimzelx. Prescribing information. UCB Inc.